MAPK3 and cancer: Sustained increased levels of phosphorylated Erk1/2 kinases up to 48 hours following treatment of T98/shRNA with PRIMA-1MET is in accordance with a growing number of studies reporting implication of Erk1/2 in promoting cell death through apoptosis in different cancer types [77].